Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 3 February 2009
Vol. 2, Issue 56, p. pc3
[DOI: 10.1126/scisignal.256pc3]


Science Signaling Podcast: 03 February 2009

Pier Paolo Pandolfi1 and Annalisa M. VanHook2

1 Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
2 Science Signaling, American Association for the Advancement of Science, 1200 New York Avenue, N.W., Washington, DC 20005, USA.

Abstract: This is a conversation with Pier Paolo Pandolfi, senior author of a Research Article published in the 27 January issue of Science Signaling. He discusses his lab's recent research on the role of signaling through the mammalian target of rapamycin (mTOR) in prostate cancer.

Citation: P. P. Pandolfi, A. M. VanHook, Science Signaling Podcast: 03 February 2009. Sci. Signal. 2, pc3 (2009).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882